Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1361-1380 of 2,120 trials

Hepatocellular Carcinoma: Durvalumab and Tremelimumab with Y-90 SIRT

We are studying a combination of immunotherapy and radiation therapy for patients with intermediate stage liver cancer who cannot have surgery. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Semaglutide for Obesity and Resistant Hypertension

We are exploring whether semaglutide can help people with obesity and resistant hypertension better control their blood pressure compared to a placebo. This study aims to assess if this approach is feasible.

Resistant HypertensionObesity6-12 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Sickle Cell Disease: CTX001 Treatment for Kids

We are studying a new gene-editing treatment for children with severe sickle cell disease. The trial aims to evaluate its safety and effectiveness in improving their health.

Sickle Cell Anaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Influenza Vaccination: Antibody Responses Study

We are investigating how intranasal and intramuscular flu vaccines affect antibody levels in the nose. This research may help improve future vaccination methods.

Healthy Participants≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

RAR-Immune: Nivolumab + Ipilimumab vs. Pazopanib for Advanced Sarcoma

We are studying whether a combination of nivolumab and ipilimumab works better than pazopanib alone for patients with advanced rare sarcomas. This trial will help us understand treatment effectiveness and patient quality of life.

Advanced Rare Sarcomas>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Venous Thromboembolism in Cancer: Abelacimab vs. Dalteparin

We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.

Venous Thromboembolism (VTE)6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ovarian Stimulation: Follitropin Delta and Dydrogesterone

We are studying a new ovarian stimulation method for egg donors to see if it produces similar results to traditional approaches. This research may help improve fertility treatments in the future.

Healthy Oocyte Donors1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Acute Myeloid Leukemia: Midostaurin and Gemtuzumab Ozogamicin

We are studying a new combination treatment for patients with acute myeloid leukemia to see if it is safe and effective alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Craniotomy Pain Management: S-Ketamine Study

We are investigating whether adding s-ketamine to standard pain relief helps reduce opioid use and improve pain control after craniotomy in patients with drug-resistant epilepsy.

Post-Craniotomy Headache6-12 monthsMonitoring phase (IV)Standard MedicinesNeurologyOtolaryngologyPsychiatry

Breast Cancer: Genomics Guided Therapy Study

We are exploring whether a personalized treatment approach after surgery can improve outcomes for patients with early high-risk breast cancer. This study will assess survival rates and the safety of the new therapy.

Early Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Retinoblastoma: New Treatment Strategies

We are studying the effectiveness of a new chemotherapy method and other conservative treatments for children with retinoblastoma. Our goal is to see how well these treatments control the disease and support visual health.

Retinoblastoma Treatment>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Colorectal Cancer: New Treatment with 5-Fluorouracil, Panitumumab, and Sotorasib

We are studying a combination of medications for patients with advanced colorectal cancer who cannot receive standard chemotherapy. The goal is to see if this treatment helps control the disease and improves quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Sepsis Treatment: Aminoglycoside Antibiotics and Isolation

We are studying the effects of combining aminoglycoside antibiotics with standard care and the role of protective isolation in critically ill neutropenic patients with sepsis. Our goal is to see how these strategies impact survival and other health outcomes.

Healthy Participants>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Type 1 Diabetes: Low-Dose Interleukin-2 Study

We are studying the effects of low-dose interleukin-2 on patients with type 1 diabetes who still have some insulin production. The aim is to see if this treatment can help improve their immune response and insulin levels.

Type 1 DiabetesEfficacy phase (II)16-20 visitsInvestigational MedicinesEndocrinologyInternal Medicine

Lung Cancer Treatment: CT-P51 vs. Keytruda

We are comparing the effects and safety of CT-P51 and Keytruda in patients with untreated metastatic lung cancer. This study aims to find out if CT-P51 works as well as Keytruda when combined with chemotherapy.

Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Colorectal Cancer: New Immunotherapy Treatment

We are studying a combination of Pembrolizumab and a Dendritic Cell Vaccine, followed by other medications, for patients with advanced colorectal cancer that hasn't responded to prior treatments. The goal is to see if this approach improves survival and safety.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Sacituzumab Govitecan with Bevacizumab for Brain Metastases in Lung Cancer

We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.

Lung Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncology

Rotator Cuff Disease: Botulinum Toxin Treatment

We are studying whether botulinum toxin can help reduce pain and improve function in people with degenerative rotator cuff disease. Participants will be monitored for effectiveness and any side effects over three months.

Shoulder Tendonitis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesOrthopedics and Traumatology